TuHURA Biosciences Inc (NASDAQ:HURA), a Florida-based Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta Inc (OTC Pink:KANT), a Washington-based clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced on Tuesday that TuHURA stockholders approved all of the proposals set forth at the company's Special Meeting of Stockholders held on 23 June 2025.
The proposals included an increase of the company's authorised shares to 200 million shares, and a proposal to reincorporate the company in Delaware.
Additionally, Kineta stockholders approved the proposed merger with TuHURA at Kineta's Special Meeting of Stockholders held on 23 June 2025. The parties anticipate that the merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.
Biovica secures European patent for biomarker use in immuno-oncology
Valneva signs exclusive German vaccine distribution deal with CSL Seqirus
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Alvotech reports positive topline results for Xolair biosimilar study
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta